PD-L1 testing is an integral part of patient care, making your expertise more important than ever. Use the Atlas of Stains: PD-L1 IHC 22C3 pharmDx to increase your familiarity and confidence in scoring PD-L1 stains.
The Atlas of Stains: PD-L1 IHC 22C3 pharmDx is a digital repository of NSCLC tissue samples stained with PD-L1 IHC 22C3 pharmDx including:
Positive cases that span the full range of PD-L1 expression
Negative cases that may demonstrate intrinsic controls (tumor associated macrophages and immune cell staining)
Full specimen staining with H&E, primary antibody, and Negative Control Reagent (NCR) for each patient
The viewer interface for the Atlas of Stains: PD-L1 IHC 22C3 pharmDx features:
High-definition, zoomable scans with full-screen and quadrant-view functionality for detailed PD-L1 stain analysis
Expert annotations describing areas of interest plus the ability to add your own annotations
Tumor Proportion Score (TPS) for each stain, to verify your own assessment
To begin exploring the Atlas, select one of the category of cases from the menu below:
For in vitro diagnostic use
PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. The specimen should be considered to have PD-L1 expression if TPS ≥ 1% and high PD-L1 expression if TPS ≥ 50%.
PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab). See the KEYTRUDA® product label for expression cutoff values guiding therapy in specific clinical circumstances.